3 min read

UBC Joins New Industry Coalition DTRA to Accelerate Decentralized Research

UBC is proud to be a founding member of the DTRA and accelerate the broad adoption of patient-focused, decentralized clinical trials and research.
UBC is proud to be a founding member and accelerate patient-focused research.

In the wake of the COVID-19 health crisis, the entire biopharmaceutical industry is coming together to ensure the advancement of patient access to critical research studies and novel treatments. Together, we are working to remove barriers to make trial and research access safe and convenient, by accelerating the adoption of technology-enabled remote data collection practices.

“We are honored to join the DTRA at such a pivotal moment for the entire healthcare system. The pandemic has presented myriad challenges for pharmaceutical manufacturers, research organizations, and regulators” said Aaron Berger, Executive Director, Late Stage Operations & RWE, a leading voice in evidence generation strategies. “To meet these challenges, a robust array of decentralized trial solutions are needed, including digital patient engagement, technology-enabled data acquisition, and in-home nursing. We are introducing one or more of these strategies into study design discussions with our sponsor partners.”

Since March, UBC’s comprehensive suite of solutions has helped many clients mitigate the risks that surround bringing treatments to market in today’s challenging environment.

“Through the utilization of direct-to-patient and digital strategies, we have been able to modernize and accelerate the way we gather critical data and insights needed for regulatory decisions and beyond. Our wide array of decentralized study capabilities to collect critical evidence beyond the walls of the traditional study setting, remotely or in the patient’s home. These are the types of experiences we are keen to share with fellow leaders and industry stakeholders as part of our role in the DTRA and the future of clinical development.” Berger concludes.

About DTRA:

The Decentralized Trials & Research Alliance (DTRA) was convened to enable collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research. It works to make research participation accessible to everyone, enabled by the consistent, widespread adoption of appropriate decentralized research methods.

For more information regarding UBC’s virtual & decentralized research solutions, head here.

Other Recent Posts

Featured Image
Press
4 min read

UBC Named a Pharmacovigilance Leader in Everest Group PV Operations PEAK Matrix Assessment 2025

UBC has been recognized by Everest Group as a leader in its 2025 Pre-approval Pharmacovigilance (PV) PEAK Matrix®, and a major contender in the Post-approval category. The recognition highlights UBC’s strength in delivering innovative, compliant, and patient-focused PV solutions across the drug development lifecycle.
Featured Image
Press
5 min read

UBC Announces Partnership with Osmind to Advance the Future of Mental Health Treatment and Research within REMS

First-of-its-kind partnership in mental health care reduces REMS implementation burden, improves the quality of REMS data, and optimizes safe medication use and health outcomes
Big data visualization depicting a network of connected people.
Press
5 min read

UBC and Thread Expand SitePlus Offering and Active Studies with BioPharma Sponsors to Optimize Evidence Generation

This augments the central site model with additional research services and tech to widen recruitment and improves site and patient experience.